• <center id="my6c6"></center>
    <rt id="my6c6"><acronym id="my6c6"></acronym></rt>
  • <abbr id="my6c6"></abbr>
  •  

    上海強世信息科技有限公司

    Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
    作者:Jin F, Gao Y, Zhou H, Fang L, Li X, Ramanathan S | 發布:yangyuting | 發布時間: 2018-08-01 | 1973 次瀏覽 | 分享到:
    ABSTRACT
    PURPOSE:
    Idelalisib is a potent PI3Kδ inhibitor that was recently approved for treating hematologic malignancies. The objective of this analysis was to develop a population pharmacokinetic model for idelalisib and its inactive metabolite GS563117 and to evaluate the impact of covariates on idelalisib/GS563117 PK.

    METHODS:
    Data from 10 phase I or II studies in healthy volunteers or patients with hematologic malignancies (n = 736) were analyzed using NONMEM. Stepwise forward addition followed by backward elimination was implemented in the covariate (age, gender, race, body weight, baseline CLcr, AST, ALT, disease status, and type of cancer) model building process. Various model assessment methods were used to evaluate the models.

    RESULTS:
    Idelalisib plasma PK was best described by a two-compartment model with first-order absorption, first-order elimination from the central compartment, and a lag time. A nonlinear relationship between dose and relative bioavailability was included in the final model. Two statistically significant covariates were identified and incorporated into the final model: health status (healthy vs. patient) on CL/F and Q/F and body weight on CL/F. Despite being a statistically significant covariate, the effect of body weight on idelalisib exposures was weak, as evidenced by minor changes of steady-state exposure (C trough: 16%; AUC and C max: 10%) for a patient with extreme body weight (5th and 95th percentile) relative to the typical patient, and not considered to be clinically relevant.

    CONCLUSIONS:
    PopPK models were developed to adequately describe the plasma concentrations of idelalisib and GS-563117. There were no covariate that had a clinically meaningful impact on idelalisib or GS-563117 exposure.
    色悠久久久久综合网香蕉| 久久大香伊人中文字幕| 国内精品伊人久久久影院| 麻豆精品久久精品色综合| 亚洲精品国产自在久久| 久久亚洲国产最新网站| 香蕉久久夜色精品升级完成| 狠狠色婷婷久久一区二区三区| 精品久久久久久久免费加勒比| 2021国内精品久久久久精免费| 国产V亚洲V天堂无码久久久| 久久国产精品免费一区| 热99re久久免费视精品频软件 | 久久99国产精品久久99| 国产三级精品久久| 色偷偷91综合久久噜噜噜男男| 91久久国产精品| 一级做a爰片久久毛片16| 亚洲精品国产字幕久久不卡| 国产毛片久久久久久国产毛片 | 国产高潮国产高潮久久久91| 精品国产乱码久久久久久 | 国产成人无码精品久久久免费| 曰产无码久久久久久精品| 久久精品天天中文字幕人妻| 久久狠狠躁免费观看| 久久久久四虎国产精品| 青青草原综合久久大伊人| 久久99亚洲综合精品首页| 一本久久A久久免费精品不卡| 久久一本人碰碰人碰| 精品久久久久久无码人妻中文字幕 | 91精品国产综合久久久久久| 香港aa三级久久三级老师2021国产三级精品三级在 | 精品一区二区久久| 久久久久久国产a免费观看不卡 | 久久国产香蕉视频| 久久精品国产99久久香蕉| 国产精品成人99久久久久| 国产福利电影一区二区三区久久老子无码午夜伦不 | 色婷婷久久综合中文久久一本`|